Lucinda Warren

Chief Financial and Business Officer (Principal Financial and Accounting Officer), Cue Biopharma, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

Lucinda Warren signed the annual report of Cue Biopharma, Inc. on Form 10-K as Chief Financial and Business Officer (Principal Financial and Accounting Officer), filed March 16, 2026.¹ A later filing by Cue Biopharma, Inc., made on August 3, 2026, names James Ahlers as its chief financial officer; the record holds no filing that reports the end of Lucinda Warren's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Cue Biopharma, Inc. (CUE) Pharmaceutical Preparations	Chief Financial and Business Officer (Principal Financial and Accounting Officer)	A later filing names a successor James Ahlers, filed August 3, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 16, 202610-K filed
Lucinda Warren signed the annual report of Cue Biopharma, Inc. on Form 10-K as Chief Financial and Business Officer (Principal Financial and Accounting Officer), filed March 16, 2026.
/s/ Lucinda Warren Chief Financial and Business Officer March 16, 2026 Lucinda Warren (Principal Financial and Accounting Officer)
[1] Annual report on Form 10-K by Cue Biopharma, Inc., filed with the SEC on March 16, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Cue Biopharma, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 16, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Lucinda Warren wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.